AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3950252
Drug: Dog allergen
RxNorm normalized name: Recombinant dog allergen 1 specific immunoglobulin E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dog allergen treatment (7 with dog allergen)
Trial: 30920245
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy for seasonal affective disorder (CBT-SAD)
Trial: 15354376
Drug: Light therapy
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light therapy
Trial: 9432453
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment group (control)
Trial: 22647089
Drug: Caffeine ingestion
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine ingestion (6 mg · kg⁻¹ body-mass)
Trial: 20096897
Drug: Soy food-containing
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy food-containing diet with 10 g/d prebiotic (oligofructose-enriched inulin)
Trial: 20096897
Drug: Prebiotic (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prebiotic (10 g/d)
Trial: 20096897
Drug: Soy food-containing
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy food-containing diet (30 g/d soy protein, 61 mg/d isoflavones) with 10 g/d placebo (maltodextrin)
Trial: 18029465
Drug: DHEA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA supplementation (50 mg/d) plus exercise training (endurance and resistance)
Trial: 15910512
Drug: AR-R15896AR 120
RxNorm normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AR-R15896AR 120 mg
Trial: 12095664
Drug: Atomoxetine 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine 90 mg
Trial: 12095664
Drug: Methylphenidate 20
RxNorm normalized name: METHYLPHENIDATE 20MG/9HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate 20 mg and 40 mg
Trial: 12095664
Drug: Atomoxetine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine 20 mg, 45 mg, and 90 mg
Trial: 9875081
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg oestradiol treatment
Trial: 31384899
Drug: SLA and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLA and DAE surface treatment methods
Trial: 26416653
Drug: telapravir (TVR)
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: telapravir (TVR) in combination with pegylated interferon and ribavirin (PegIFN/R)
Trial: 24640205
Drug: Badriphal (Hippophae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Badriphal (Hippophae rhamnoides) 350 mg twice daily for 3 months
Trial: 17852127
Drug: Open-label stimulant
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label stimulant medication
Trial: 16824073
Drug: CH100 (Chinese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CH100 (Chinese herbal therapy)
Trial: 14616189
Drug: Tiagabine 12
RxNorm normalized name: tiaGABine 12 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine 12 mg/day
Trial: 14616189
Drug: Active medications
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active medications (Tiagabine 12 mg/day and 24 mg/day)
Trial: 21207091
Drug: EAC (esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EAC (esomeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, all b.i.d. for 8 days)
Trial: 21207091
Drug: EACL (EAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EACL (EAC plus Lactobacillus acidophilus, 5 × 10(9) organisms per capsule, 3 + 2 i.d. for 8 days)
Trial: 15577587
Drug: Post-injection transmission-based
RxNorm normalized name: post oak pollen extract Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-injection transmission-based segmented attenuation correction (SAC) technique
Trial: 31669562
Drug: Clonidine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (both doses)
Trial: 23464930
Drug: Low-dose SPAA
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose SPAA (5/10 or 10/10 mg)
Trial: 20010119
Drug: Spirulina (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirulina (6 g x d(‐1))
Trial: 16860045
Drug: Depot medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depot medroxyprogesterone acetate (DMPA) 150 mg/mL
Trial: 9010008
Drug: Suramin administered
RxNorm normalized name: suramin
DrugBank: Suramin (DB04786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suramin administered intravenously in escalating dosages (300, 350, and 400 micrograms ml-1)
Trial: 9010008
Drug: Suramin administered
RxNorm normalized name: suramin
DrugBank: Suramin (DB04786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suramin administered intravenously in escalating dosages (350 and 400 micrograms ml-1)
Trial: 9010008
Drug: Suramin administered
RxNorm normalized name: suramin
DrugBank: Suramin (DB04786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suramin administered intravenously with neurological monitoring
Trial: 9010008
Drug: Suramin with
RxNorm normalized name: suramin
DrugBank: Suramin (DB04786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suramin with drug discontinuation and plasmapheresis
Trial: 1509986
Drug: AM3 (glycophosphopeptide),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AM3 (glycophosphopeptide), 1 g daily for 4 months
Trial: 30292481
Drug: Cocktail of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocktail of 12 natural lytic anti‐Pseudomonas aeruginosa bacteriophages (PP1131; 1 × 106 PFU/mL) applied as a daily topical treatment for 7 days.
Trial: 30292481
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (1% sulfadiazine silver emulsion cream) applied as a daily topical treatment for 7 days.
Trial: 30292481
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (1% sulfadiazine silver emulsion cream).
Trial: 27739232
Drug: Intramuscular bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular bolus injections of 30 mg of ketorolac tromethamine every 6 hours (total daily dose of 120 mg)
Trial: 26770927
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E therapy (n=58)
Trial: 11251350
Drug: Extended out‐of‐hospital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended out‐of‐hospital prophylaxis with low‐molecular‐weight heparin
Trial: 8348279
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg methylprednisolone and lignocaine
Trial: 30350406
Drug: Integrated intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated intervention combining health systems navigation and psychosocial counselling for early engagement of antiretroviral therapy (ART) and substance use treatment for PWID living with HIV.
Trial: 12766095
Drug: Monthly remunerated
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly remunerated routine chiropodist care (n = 47)
Trial: 8844033
Drug: Diazepam loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam loading dose therapy (40 to 210 mg, mean 86.9 ± 47.2 mg)
Trial: 8844033
Drug: Traditional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional therapy (diazepam and other psychotropic drugs in divided doses)
Trial: 6345501
Drug: Propranolol (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (up to 120 mg per day)
Trial: 22811410
Drug: Cisplatin 7
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 7 mg/m² Days 1-5, 8-12, 29-33 and 36-40 and 5-fluorouracil 250 mg/m² Days 1-14 and 29-42 with the same radiotherapy (arm B)
Trial: 19069889
Drug: Oxytocin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin (6 mu min(‐1) infusion)
Trial: 16245968
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C (0.2 mg/mL for 5 min)
Trial: 12081834
Drug: Beta-carotene supplementation
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene supplementation (30 mg/d)
Trial: 8583134
Drug: 3 million
RxNorm normalized name: INTERFERON GAMMA-1B 3 MILLION UNT/0.5ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 million units of interferon alfa‐2b thrice weekly for 6 months
Trial: 8583134
Drug: 5 million
RxNorm normalized name: colistin 1.5 million UNT Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 million units of interferon alfa‐2b thrice weekly for 6 months
Trial: 8583134
Drug: 3 million
RxNorm normalized name: INTERFERON GAMMA-1B 3 MILLION UNT/0.5ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 million units of interferon alfa‐2b thrice weekly for 2 years
Trial: 8583134
Drug: 2 years
RxNorm normalized name: Childrens Panadol 5 - 12 Years
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 years treatment
Trial: 8583134
Drug: Injecting drug
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injecting drug use
Trial: 8583134
Drug: 2 years
RxNorm normalized name: Childrens Panadol 5 - 12 Years
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 years treatment vs 6 months treatment
Trial: 30513252
Drug: DTaP‐IPV‐HB‐PRPT primary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP‐IPV‐HB‐PRPT primary and booster vaccination with birth dose of HB
Trial: 30513252
Drug: DTaP‐IPV‐HB‐PRPT primary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP‐IPV‐HB‐PRPT primary and booster vaccination without birth dose of HB
Trial: 21542734
Drug: 1% alendronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% alendronate gel
Trial: 14597353
Drug: Higher total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher total dose irradiation or prophylactic surgery
Trial: 28143564
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) administered within 3 hours of injury
Trial: 28143564
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) administered after 3 hours of injury
Trial: 28143564
Drug: Subgroup analyses
RxNorm normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subgroup analyses for early TXA treatment
Trial: 28143564
Drug: Subgroup analyses
RxNorm normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subgroup analyses for late TXA treatment
Trial: 23022602
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein yogurt snack (24 g protein)
Trial: 23022602
Drug: Moderate protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate protein yogurt snack (14 g protein)
Trial: 23022602
Drug: Low protein
RxNorm normalized name: Low protein mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low protein yogurt snack (5 g protein)
Trial: 20671652
Drug: Low-dose atorvastatin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose atorvastatin, titrated to maintain LDL cholesterol <100 mg/dL
Trial: 17989103
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) at 2 g/day for 6 months along with prednisolone at 0.5 mg/kg/day for 2-3 months
Trial: 17989103
Drug: Conventional therapy:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy: prednisolone 1 mg/kg/day for 3-6 months for FSGS and alternating monthly cycles of steroids and cyclophosphamide for 6 months for MN
Trial: 10540048
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Alpha2b‐interferon + ketoprofen 200 mg/day five times weekly)
Trial: 8551786
Drug: Nafamostat (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafamostat (2 mg/kg per hour) during cardiopulmonary bypass
Trial: 24206588
Drug: Artesunate (AS)
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artesunate (AS) monotherapy
Trial: 12417888
Drug: Fexofenadine 180
RxNorm normalized name: fexofenadine 180 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine 180 mg
Trial: 9350366
Drug: Nicardipine (0.017
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (0.017 mg.kg‐1) with isoflurane
Trial: 9350366
Drug: Nicardipine (0.017
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (0.017 mg.kg‐1) with enflurane
Trial: 8186346
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg b.d.
Trial: 7986969
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg q.d.s.
Trial: 1486156
Drug: Ranitidine 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 600 mg b.d.
Trial: 31779697
Drug: PG102P 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PG102P 1.5 g/day
Trial: 17179242
Drug: Intraoperative cerebral
RxNorm normalized name: Sus scrofa cerebral cortex preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative cerebral regional oxygen saturation (rSO2) monitoring with active display and treatment intervention protocol (n = 100)
Trial: 15369567
Drug: Outpatient chemical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient chemical dependency treatment
Trial: 14607566
Drug: Ketoconazole (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (50 mg every 48 hours) with hMG
Trial: 8580277
Drug: Fluconazole oral
RxNorm normalized name: fluconazole Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole oral suspension
Trial: 8877335
Drug: Ulfon Lyoc
RxNorm normalized name: Dimethyl sulfone
DrugBank: Dimethyl sulfone (DB14090)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulfon Lyoc and Ulfon suspension
Trial: 6356322
Drug: Sucralfate 500
RxNorm normalized name: sucralfate 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate 500 mg before breakfast, lunch, supper and 1000 mg on retiring
Trial: 3083505
Drug: Auranofin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auranofin (6 mg/day)
Trial: 10468203
Drug: Alpha-lipoic acid
RxNorm normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-lipoic acid (ALA) 600 mg once daily
Trial: 20064022
Drug: Hypericum perforatum
RxNorm normalized name: Hypericum perforatum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypericum perforatum ointment
Trial: 28027682
Drug: Achillea millefolium
RxNorm normalized name: ACHILLEA MILLEFOLIUM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Achillea millefolium ointment
Trial: 1124717
Drug: Propranolol 80
RxNorm normalized name: propranolol 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 80 mg/day
Trial: 12655535
Drug: Oral ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ciprofloxacin (Group A)
Trial: 8648360
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA) 500 mg twice daily
Trial: 1498502
Drug: Bovine surfactant
RxNorm normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bovine surfactant preparation (SF‐RI 1)
Trial: 15110926
Drug: Intravenous alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alcohol infusion
Trial: 31735560
Drug: Pomalidomide 4
RxNorm normalized name: pomalidomide 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomalidomide 4 mg plus dexamethasone 40 mg
Trial: 22617578
Drug: Continuous oral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous oral contraceptive pills (gestodene 0.075 mg and ethinyl estradiol 20 microgram) for 6 months
Trial: 22617578
Drug: Cyclic oral
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic oral contraceptive pills (gestodene 0.075 mg and ethinyl estradiol 20 microgram) for 6 months
Trial: 22617578
Drug: Continuous oral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous oral contraceptive pills
Trial: 22617578
Drug: Cyclic oral
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic oral contraceptive pills
Trial: 20223838
Drug: Methylprednisolone (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (120 mg intramuscular injection)
Trial: 11144061
Drug: Treatment (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment (specific treatment details not provided)
Trial: 8809925
Drug: Low-dosage or
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dosage or short-time exercise programs
Trial: 12854476
Drug: PGE1 infusion
RxNorm normalized name: PGE1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PGE1 infusion
Trial: 6332953
Drug: Propranolol 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 0.05 mg/kg administered 4 to 5 minutes before aortic cross‐clamping
Trial: 29725956
Drug: Sacchaflor (S.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacchaflor (S. boulardii 5 × 10^9, Pharmaforce ApS) twice daily
Trial: 26956679
Drug: Culturally informed
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally informed intervention including regular postcards, problem solving therapy, patient support, risk management, improved access to primary care, and cultural assessment in addition to usual care.
Trial: 22499404
Drug: conventional Chest
RxNorm normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: conventional Chest Physical therapy (cCPT)
Trial: 20042424
Drug: Optimized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized treatment only (Control group)
Trial: 23551402
Drug: Melatonin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (10 mg/kg) for 4 weeks
Trial: 813951
Drug: Ibuprofen total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen total daily dose 1,200 mg
Trial: 813951
Drug: Warfarin 7.5
RxNorm normalized name: warfarin 7.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin 7.5 mg
Trial: 23660437
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of the DRD2 agonist bromocriptine
Trial: 21221531
Drug: Varenicline 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline 2 mg daily (extended 4-week pretreatment)
Trial: 21221531
Drug: Usual 1-week
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual 1-week pretreatment (placebo lead in followed by active medication)
Trial: 8757207
Drug: Double-strength beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-strength beclomethasone dipropionate (BDP-ds) aqueous nasal spray (84 micrograms/spray), once daily
Trial: 2997101
Drug: Intravenous acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous acyclovir 250 mg/m2 once daily for four weeks
Trial: 2997101
Drug: Intravenous acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous acyclovir 250 mg/m2 once daily
Trial: 31420703
Drug: Cinnarizine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnarizine (25 mg) plus Betahistine (8 mg) combination, administered three times a day for 1 week
Trial: 15237711
Drug: GnRH analog
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH analog treatment (triptorelin or leuprolide acetate)
Trial: 28012176
Drug: UE2343 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UE2343 (10 mg and above)
Trial: 25889354
Drug: Low-protein pancake
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-protein pancake breakfast (3 g protein)
Trial: 11350703
Drug: Paroxetine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (10 mg to 40 mg per day)